Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
16 hedge funds and large institutions have $81.4M invested in Evofem Biosciences, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
49% more capital invested
Capital invested by funds: $54.7M → $81.4M (+$26.8M)
14% more funds holding
Funds holding: 14 → 16 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$940K |
| 2 |
TWMP
Taylor Wealth Management Partners
Boston,
Massachusetts
|
+$750K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$627K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$98.8K |
| 5 |
IA
Independence Advisors
Wayne,
Pennsylvania
|
+$28.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.61M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.03M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$23.9K |
| 4 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$3K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$1K |
EVFM Hedge Fund Activity: Q3 2018 in Review
16 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2018, worth a combined $81.4M — up 49% from $54.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVFM positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Heartland Advisors, opening a new position worth an estimated $940K. The largest seller was Millennium Management, cutting an estimated $1.61M.
- 16 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2018, up from 14 in Q2 2018.
- Funds reported $81.4M of Evofem Biosciences, Inc. Common Stock stock for Q3 2018, up 49% quarter-over-quarter.
- 5 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2018 and 3 closed out, a net change of +2 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2018 was Heartland Advisors, an estimated $940K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2018 was Millennium Management, an estimated $1.61M sold.
Based on aggregated 13F filings for Q3 2018.